QUICK SEARCH:

[advanced]

	Author:		Keyword(s):

Home Help Feedback Subscriptions Archive Search Table of Contents

	Help viewing high resolution images
	Return to article

(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 6. Expression of endothelial cell markers in FGFR-1 ^-/- EBs. (A) Real-time PCR to determine CD31, VEGF-C, Ephrin B2 and VEGFR-2, VEGFR-1, VEGF-A transcription levels in 8-day-old FGFR^+/- (+/-) or FGFR^-/- (-/-) EBs cultured in basal conditions (i.e. without addition of exogenous growth factors). Changes are relative to ß-actin transcript levels. (B; right) Immunohistochemical staining for VEGFR-2 in FGFR-1^-/- EBs cultured for 8 days under basal condition. Scale bars: 200 µm. (Left) Expression of VEGFR-2 protein in total cell lysates of basal treated FGFR-1^+/- (+/-) and FGFR-1^-/- (-/-) 8-day-old EBs. ß-catenin was used as loading control. (C) Immunocomplex kinase assay of VEGFR-2 on day-8 FGFR-1^+/- (+/-) or FGFR-1^-/- (-/-) EBs cultured under basal conditions (without exogenous growth factors) and unstimulated (-) or stimulated (+) with 100 ng/ml of VEGF-A for 10 minutes. Slower migrating, kinase active VEGFR-2 appeared in the FGFR-1^-/- EBs (arrowhead). (D) CD31 staining of FGFR-1^-/- EBs in basal conditions treated with either control anti-rat IgG, neutralizing anti-VEGFR-2 (30 µg/ml), or anti-VEGF-A (5 µg/ml) antibodies from day 6-8. Scale bars: 200 µm. (E) Quantification of CD31 staining as area (i.e. area without holes) in 8-day FGFR-1^-/- EBs treated with anti-VEGFR-2 or anti-VEGF-A antibodies from day 6-8. Results are expressed as percentage of FGFR-1^-/- EBs treated with control IgG (mean±s.d., n=4). ^*P=0.002 for anti-VEGFR-2 treatment compared to control. ^*P=0.0306 for anti-VEGF-A treatment compared to control.

Return to article